-
公开(公告)号:CA1326661C
公开(公告)日:1994-02-01
申请号:CA563413
申请日:1988-04-06
Applicant: ABBOTT LAB
Inventor: GRENIER FRANK C , PRY TERRY A , KOLACZKOWSKI LAWRENCE
Abstract: A method for performing a diagnostic immunoassay by solid phase separation for digoxin. To a reaction mixture of a test sample and labeled anti-digoxin antibody, which forms a complex of any digoxin present in the test sample, is added a solid phase material having an immobilized ouabain triacetate derivative compound capable of binding any excess labeled antibody. The solid phase material is chosen to rapidly settle whereby a solid and liquid phase is formed. The liquid phase can then be extracted to measure the amount of digoxin-labeled antibody present therein. Ouabain triacetate derivative compounds possess sufficient affinity for anti-digoxin antibodies, and are therefore useful in a solid phase separation based digoxin immunoassay for settling out such antibodies without contributing to undesired background interference. These compounds are also less deleterious to assay performance because of low recognition when leached from the solid phase matrix thereby providing solid phase material with extended shelf life.
-
公开(公告)号:CA2032228A1
公开(公告)日:1991-06-23
申请号:CA2032228
申请日:1990-12-13
Applicant: ABBOTT LAB
Inventor: KOLACZKOWSKI LAWRENCE , LITTLEFIELD MARK
IPC: G01N33/52 , A61K49/00 , C07D227/00 , C07D493/10 , C07K14/435 , C07K14/76 , C07K14/765 , C09B11/08 , C09B11/28 , C09B29/12 , G01N33/53 , G01N33/533
Abstract: A substituted monoethylglycinexylidide or analogue is disclosed. The xylidide or analogue has the structure of Fig. 1 of the attached drawings where M is CH2NHCH2CH3, CH2CH2CH2CH3 or CH2OCH2CH3, one of Y1 and Y2 is H and the other is a protein or a fluorescein moiety chemically bonded to the glycinexylidide or analogue moiety. Also disclosed is a method for carrying out immunoassays for MEGX, which has the structure of Fig. 3 of the attached drawings. The method for carrying out immunoassays involves using the foregoing compounds as tracers and immunogens. 21
-
公开(公告)号:DOP2010000099A
公开(公告)日:2017-04-30
申请号:DO2010000099
申请日:2010-04-08
Applicant: ABBOTT LAB
Inventor: KOLACZKOWSKI LAWRENCE
IPC: A61K31/4184 , A61P35/00 , C07D487/04
Abstract: En la presente solicitud se describe la forma cristalina 1 de 2-((R)-2-metilpirrolidin-2- il)-1H-benzimidazol-4-carboxamida (ABT-888), un inhibidor de la poli(ADP-ribosa) polimerasa (PARP) útil contra diferentes tipos de cánceres, tales como rabdomiosarcoma embrionario, leucemia linfoblástica aguda pediátrica, linfoma anaplásico de células grandes pediátrico, meduloblastoma anaplásico pediátrico, tumor de riñón rabdoide pediátrico, rabdomiosarcoma pediátrico, cánceres pediátricos de células T tales como linfoma, cáncer de piel y similares, etc. La base libre utilizada en la formulación de la presente invención es muy ventajosa debido a que ayuda a mejorar la tolerabilidad del fármaco, además de que incluye un 30% de incremento en la potencia del ingrediente farmacéuticamente activo en la formulación y una mejora en la compatibilidad con excipientes, en donde se evitan los microambientes altamente ácidos. La presente invención describe además las composiciones que comprenden la forma cristalina 1 y procesos para prepararla.
-
公开(公告)号:UA101961C2
公开(公告)日:2013-05-27
申请号:UAA201005713
申请日:2008-10-10
Applicant: ABBOTT LAB
Inventor: KOLACZKOWSKI LAWRENCE
IPC: C07D403/04 , A61K31/4184 , A61P35/00
Abstract: Раскрытакристаллическаяформа 1 2-((R)-2-метилпирролидин-2-ил)-1Н-бензимидазол-4-карбоксамида, способаееполучения, композиции, которыееесодержати изготовленныес ееиспользованием, испособалеченияпациентов, которыеимеютзаболевание, сееиспользованием.
-
35.
公开(公告)号:SG188878A1
公开(公告)日:2013-04-30
申请号:SG2013017603
申请日:2007-02-16
Applicant: ABBOTT LAB
Inventor: COWART MARLON D , ZHAO CHEN , SUN MINGHUA , BLACK LAWRENCE A , ZHENG GUO ZHU , GREGG ROBERT J , ZHANG GEOFF G Z , SHEIKH AHMAD Y , LOU XIAOCHUN , HENRY RODGER F , BARNES DAVID M , KOLACZKOWSKI LAWRENCE , HAIGHT ANTHONY R , CHANG SOU-JEN , WITTENBERGER STEVEN J , FICKES MICHAEL G
Abstract: Octahydro-pyrrolo[3,4-b]pyrrole derivatives are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Octahydro-pyrrolo[3,4-b]pyrrole compounds, methods for using such compounds, compositions for making them, and processes for preparing such compounds are disclosed herein.Figure 1
-
36.
公开(公告)号:SG170033A1
公开(公告)日:2011-04-29
申请号:SG2011013430
申请日:2007-02-16
Applicant: ABBOTT LAB
Inventor: COWART MARLON D , ZHAO CHEN , SUN MINGHUA , BLACK LAWRENCE A , ZHENG GUO ZHU , GREGG ROBERT J , ZHANG GEOFF G Z , SHEIKH AHMAD Y , LOU XIAOCHUN , HENRY RODGER F , BARNES DAVID M , KOLACZKOWSKI LAWRENCE , HAIGHT ANTHONY R , CHANG SOU-JEN , WITTENBERGER STEVEN J , FICKES MICHAEL G
Abstract: OCTAHYDRO-PYRROLO[3,4-B] PYRROLE DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTOR LIGANDS Octahydro-pyrrolo[3,4-b]pyrrole derivatives are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Octahydro-pyrrolo[3,4-b]pyrrole compounds, methods for using such compounds, compositions for making them, and processes for preparing such compounds are disclosed herein.
-
公开(公告)号:MX2010003772A
公开(公告)日:2010-04-21
申请号:MX2010003772
申请日:2008-10-10
Applicant: ABBOTT LAB
Inventor: KOLACZKOWSKI LAWRENCE
IPC: C07D487/04 , A61K31/4184 , A61P35/00
Abstract: Se describe la Forma Cristalina 1 de 2-((R)-2-metilpirrolidin-2- il)-1 H-bencimidazol-4-carboxamida, formas de elaborarla, composiciones que comprenden, obtenci?n, uso, y m?todos para el tratamiento de pacientes enfermos que la utilizan.
-
公开(公告)号:ECSP088687A
公开(公告)日:2008-09-29
申请号:ECSP088687
申请日:2008-08-20
Applicant: ABBOTT LAB
Inventor: SHEIKH AHMAD YAHYA , ZHAO CHEN , HAIGHT ANTHONY R , COWART MARLON D , SUN MINGHUA , ZHENG GUO ZHU , HENRY RODGER F , WITTENBERGER STEVEN J , BARNES DAVID , BLACK LAWRENCE A , GREGG ROBERT J , ZHANG GEOFF G Z , LOU XIAOCHUN , KOLACZKOWSKI LAWRENCE , CHANG SOU-JEN , FICKES MICHAEL G
IPC: A61K31/407
Abstract: Derivados de octahidro-pirrolo[3,4-b]pirrol útiles para tratar condiciones o trastornos que se previenen o mejoran con ligandos del receptor de histamina-3. En la presente se divulgan compuestos octahidro-pirrolo[3,4-b]pirrol, métodos para usar dichos compuestos, composiciones para hacerlos, y procesos para preparar dichos compuestos.
-
公开(公告)号:NZ510328A
公开(公告)日:2005-01-28
申请号:NZ51032896
申请日:1996-12-06
Applicant: ABBOTT LAB
Inventor: SHAM HING LEUNG , NORBECK DANIEL W , KEMPF DALE J , COOPER ARTHUR J , OLIVER PATRICIA A , LIU JIH-HEH J , STONER ERIC J , PLATA DANIEL J , BETEBENNER DAVID A , HERRIN THOMAS R , CONDON STEPHEN L , DICKMAN DANIEL A , KOLACZKOWSKI LAWRENCE , STENGEL PETER J , TIEN JIEH-HUA , PATEL KETAN M , HANNICK STEVEN M , KUMAR GONDI N , CHEN XIAOQI
IPC: A61K31/00 , C07D253/00 , A61K31/40 , A61K31/4015 , A61K31/41 , A61K31/415 , A61K31/4164 , A61K31/4166 , A61K31/4184 , A61K31/42 , A61K31/421 , A61K31/425 , A61K31/427 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/47 , A61K31/495 , A61K31/496 , A61K31/4965 , A61K31/505 , A61K31/513 , A61K31/53 , A61K31/55 , A61K38/05 , A61K45/00 , A61P31/18 , A61P43/00 , C07C231/12 , C07C235/20 , C07C273/18 , C07C275/16 , C07D20060101 , C07D207/22 , C07D207/26 , C07D207/27 , C07D207/273 , C07D207/34 , C07D207/40 , C07D207/404 , C07D207/408 , C07D207/416 , C07D211/72 , C07D211/84 , C07D223/06 , C07D233/28 , C07D233/30 , C07D233/32 , C07D233/36 , C07D233/40 , C07D233/42 , C07D233/66 , C07D239/06 , C07D239/10 , C07D239/20 , C07D239/22 , C07D241/06 , C07D241/08 , C07D241/18 , C07D243/04 , C07D253/06 , C07D263/16 , C07D263/20 , C07D263/22 , C07D263/34 , C07D265/04 , C07D267/04 , C07D277/12 , C07D277/32 , C07D277/34 , C07D279/06 , C07D281/02 , C07D401/12 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12
Abstract: The compound (2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxyl-5-[2S-(1-tetrahydro-pyrimid-2-only)-3-methylbutanoyl]amino-1,6-diphenylhexane, amorphous forms, and amorphous solid forms are claimed. Also claimed is the use of the compound in the manufacture of medicaments and medicaments containing the compound for the treatment of HIV infection and for inhibiting HIV protease. (62) Divided out of 338003
-
公开(公告)号:CZ294246B6
公开(公告)日:2004-11-10
申请号:CZ176298
申请日:1996-12-06
Applicant: ABBOTT LAB
Inventor: SHAM HING LEUNG , NORBECK DANIEL W , CHEN XIAOQI , BETEBENNER DAVID A , KEMPF DALE J , HERRIN THOMAS R , KUMAR GONDI N , CONDON STEPHEN L , COOPER ARTHUR J , DICKMAN DANIEL A , HANNICK STEVEN M , KOLACZKOWSKI LAWRENCE , OLIVER PATRICIA A , PLATA DANIEL J , STENGEL PETER J , STONER ERIC J , TIEN JIEH-HEH J , LIU JIH-HUA , PATEL KETAN M
IPC: C07D253/00 , A61K31/00 , A61K31/40 , A61K31/4015 , A61K31/41 , A61K31/415 , A61K31/4164 , A61K31/4166 , A61K31/4184 , A61K31/42 , A61K31/421 , A61K31/425 , A61K31/427 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/47 , A61K31/495 , A61K31/496 , A61K31/4965 , A61K31/505 , A61K31/513 , A61K31/53 , A61K31/55 , A61K38/05 , A61K45/00 , A61P31/18 , A61P43/00 , C07C231/12 , C07C235/20 , C07C273/18 , C07C275/16 , C07D20060101 , C07D207/22 , C07D207/26 , C07D207/27 , C07D207/273 , C07D207/34 , C07D207/40 , C07D207/404 , C07D207/408 , C07D207/416 , C07D211/72 , C07D211/84 , C07D223/06 , C07D233/28 , C07D233/30 , C07D233/32 , C07D233/36 , C07D233/40 , C07D233/42 , C07D233/66 , C07D239/06 , C07D239/10 , C07D239/20 , C07D239/22 , C07D241/06 , C07D241/08 , C07D241/18 , C07D243/04 , C07D253/06 , C07D263/16 , C07D263/20 , C07D263/22 , C07D263/34 , C07D265/04 , C07D267/04 , C07D277/12 , C07D277/32 , C07D277/34 , C07D279/06 , C07D281/02 , C07D401/12 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12 , C07D233/22 , A61P31/00 , A61P31/22
Abstract: In the present invention, there is described a compound of the general formula I functioning a HIV protease inhibitor. Methods and compositions for inhibiting a HIV infection are disclosed, too.
-
-
-
-
-
-
-
-
-